An Overview on Dementia: A Major Symptom of Alzheimer's Disease
Abstract
Dementia is a word for an acquired illness in which two or more cognitive abilities are lost due to a brain disease or injury. The most common form of dementia is Alzheimer's type dementia (DAT). It has been associated to cerebral cortical degenerative anomalies. It's also visible in neurologic diseases that primarily affect subcortical systems such as the basal ganglia and brain stem. The causes are plaques of β-amyloid and tangles of intraneuronal tau protein. Dementia is addressed in this overview. Pathophysiology, epidemiology, and different varieties of dementia; contributing factors to dementia; symptoms, causes, diagnosis, prevention, and care; and new breakthroughs in dementia treatment. It also looks at how patients with mental problems coped during the COVID-19 outbreak. Patients may require more therapies to manage their illness, and some future drugs are now being explored.
Keywords: Dementia, Alzheimer's, Plaques, Cognitive training, β-amyloid
Keywords:
Dementia, Alzheimer's, Plaques, Cognitive training, β-amyloid
Downloads
Download data is not yet available.
References
1. Carson SA, Kallen AN. Diagnosis and Management of Infertility: A Review. JAMA - J Am Med Assoc. 2021;326(1):65–76.
2. Gale SA, Acar D, Daffner KR. Dementia. Am J Med. 2018;131(10):1161–9.
3. Huber SJ, Shuttleworth EC, Bellchambers MJG, Clapp LE. Subcortical Dementia Neuropsychological Differences. 2015;10–2.
4. Albert ML, Feldman RG, Willis AL. The “subcortical dementia” of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1974;37(2):121–30.
5. El C, Mcguinness B, Herron B, Ap P. Dementia. 2015;84(April):79–87.
6. Calderon-Garcidueñas AL, Duyckaerts C. Alzheimer disease. Handb Clin Neurol. 2018;145:325–37.
7. Boller F, Mizutani T, Roessmann U, Gambetti P. Parkinson disease, dementia, and alzheimer disease: Clinicopathological correlations. Ann Neurol. 1980;7(4):329–35.
8. Sabbagh MN, Cooper K, DeLange J, Stoehr JD, Thind K, Lahti T, et al. Functional, Global and Cognitive Decline Correlates to Accumulation of Alzheimers Pathology in MCI and AD. Curr Alzheimer Res. 2010;7(4):280–6.
9. Beal E. Alzheimer disease: Nat Rev Neurol. 2011;7(9):474.
10. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10(2):122–6.
11. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–46.
12. Ahmadi-Abhari S, Guzman-Castillo M, Bandosz P, Shipley MJ, Muniz-Terrera G, Singh-Manoux A, et al. Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: Modelling study. BMJ. 2017;358(July):1–15.
13. Kingston A, Comas-Herrera A, Jagger C. Forecasting the care needs of the older population in England over the next 20 years: estimates from the Population Ageing and Care Simulation (PACSim) modelling study. Lancet Public Heal. 2018;3(9):e447–55.
14. Xu H, Garcia-Ptacek S, Jönsson L, Wimo A, Nordström P, Eriksdotter M. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology. 2021;96(17):e2220–30.
15. Valenzuela MJ, Sachdev P. Brain reserve and dementia: A systematic review. Psychol Med. 2006;36(4):441–54.
16. Valenzuela MJ. Brain reserve and the prevention of dementia. Curr Opin Psychiatry. 2008;21(3):296–302.
17. Wilson RS, De Mendes Leon CF, Barnes LL. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. Prim Care Companion J Clin Psychiatry. 2002;4(2):84–5.
18. Capone C, Faraco G, Park L, Cao X, Davisson RL, Iadecola C. The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am J Physiol - Hear Circ Physiol. 2011;300(1):397–407.
19. Luchsinger JA, Gustafson DR. Adiposity and Alzheimer’s disease. Curr Opin Clin Nutr Metab Care. 2009;12(1):15–21.
20. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–734.
21. Morkem R, Barber D, Williamson T, Patten SB. A Canadian primary care sentinel surveillance network study evaluating antidepressant prescribing in Canada from 2006 to 2012. Can J Psychiatry. 2015;60(12):564–70.
22. Emilsson JF, Andreasson U, Blennow K, Eriksson E, Zetterberg H. Comment on “An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice.” Sci Transl Med. 2014;6(268):268le5.
23. Yaffe K. Metabolic syndrome and cognitive disorders: Is the sum greater than its parts? Alzheimer Dis Assoc Disord. 2007;21(2):167–71.
24. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: An analysis of population-based data. Lancet Neurol. 2014;13(8):788–94.
25. Swan GE, Lessov-Schlaggar CN. The effects of tobacco smoke and nicotine on cognition and the brain. Neuropsychol Rev. 2007;17(3):259–73.
26. Yang YC, Boen C, Gerken K, Li T, Schorpp K, Harris KM. Social relationships and physiological determinants of longevity across the human life span. Proc Natl Acad Sci U S A. 2016;113(3):578–83.
27. Khaw KT, Wareham N, Bingham S, Welch A, Luben R, Day N. Combined impact of health behaviours and mortality in men and women: The EPIC-Norfolk prospective population study. PLoS Med. 2008;5(1):0039–47.
28. Sabia S, Dugravot A, Dartigues JF, Abell J, Elbaz A, Kivimäki M, et al. Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. BMJ [Internet]. 2017;357(June):1–12. Available from: http://dx.doi.org/doi:10.1136/bmj.j2709
29. Singh-Manoux A, Dugravot A, Fournier A, Abell J, Ebmeier K, Kivimäki M, et al. Trajectories of depressive symptoms before diagnosis of dementia: A 28-year follow-up study. JAMA Psychiatry. 2017;74(7):712–8.
30. Deckers K, Van Boxtel MPJ, Schiepers OJG, De Vugt M, Sánchez JLM, Anstey KJ, et al. Target risk factors for dementia prevention: A systematic review and Delphi consensus study on the evidence from observational studies. Int J Geriatr Psychiatry. 2015;30(3):234–46.
31. Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med. 2016;374(6):523–32.
32. Larsson SC, Traylor M, Malik R, Dichgans M, Burgess S, Markus HS. Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis. BMJ. 2017;359:j5375.
33. Kremen WS, Beck A, Elman JA, Gustavson DE, Reynolds CA, Tu XM, et al. Influence of young adult cognitive ability and additional education on later-life cognition. Proc Natl Acad Sci U S A. 2019;116(6):2021–6.
34. Blacker D, Weuve J. Brain exercise and brain outcomes: Does cognitive activity really work to maintain your brain? JAMA Psychiatry. 2018;75(7):703–4.
35. Lee ATC, Richards M, Chan WC, Chiu HFK, Lee RSY, Lam LCW. Association of daily intellectual activities with lower risk of incident dementia among older Chinese adults. JAMA Psychiatry. 2018;75(7):697–703.
36. Girouard H, Park L, Anrather J, Zhou P, Iadecola C. Cerebrovascular nitrosative stress mediates neurovascular and endothelial dysfunction induced by angiotensin II. Arterioscler Thromb Vasc Biol. 2007;27(2):303–9.
37. McGrath ER, Seshadri S. Author response: Blood pressure from mid- to late life and risk of incident dementia. Neurology. 2018;91(3):149.
38. Lane CA, Barnes J, Nicholas JM, Sudre CH, Cash DM, Parker TD, et al. Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. Lancet Neurol [Internet]. 2019;18(10):942–52. Available from: http://dx.doi.org/10.1016/S1474-4422(19)30228-5
39. Abell JG, Kivimäki M, Dugravot A, Tabak AG, Fayosse A, Shipley M, et al. Association between systolic blood pressure and dementia in theWhitehall II cohort study: Role of age, duration, and threshold used to define hypertension. Eur Heart J. 2018;39(33):3119–25.
40. Cholerton B, Larson EB, Baker LD, Craft S, Crane PK, Millard SP, et al. Neuropathologic correlates of cognition in a population-based sample. J Alzheimer’s Dis. 2013;36(4):699–709.
41. Chatterjee S, Peters SAE, Woodward M, Arango SM, Batty GD, Beckett N, et al. Type 2diabetes as a risk factor for dementia in women compared with men: A pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016;39(2):300–7.
42. Sabia S, Fayosse A, Dumurgier J, Schnitzler A, Empana JP, Ebmeier KP, et al. Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 Year follow-up of Whitehall II cohort study. BMJ. 2019;366:1–10.
43. Rehm J, Hasan OSM, Black SE, Shield KD, Schwarzinger M. Alcohol use and dementia: A systematic scoping review 11 Medical and Health Sciences 1117 Public Health and Health Services. Alzheimer’s Res Ther. 2019;11(1):1–11.
44. Schwarzinger M, Pollock BG, Hasan OSM, Dufouil C, Rehm J, Baillot S, et al. Contribution of alcohol use disorders to the burden of dementia in France 2008–13: a nationwide retrospective cohort study. Lancet Public Heal. 2018;3(3):e124–32.
45. Knutson JS. 基因的改变NIH Public Access. Bone [Internet]. 2014;23(1):1–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf
46. Debanne SM, Bielefeld RA, Cheruvu VK, Fritsch T, Rowland DY. Alzheimer’s disease and smoking: Bias in cohort studies. J Alzheimer’s Dis. 2007;11(3):313–21.
47. Choi D, Choi S, Park SM. Effect of smoking cessation on the risk of dementia: a longitudinal study. Ann Clin Transl Neurol. 2018;5(10):1192–9.
48. Öberg M, Jaakkola MS, Woodward A, Peruga A, Prüss-Ustün A. Worldwide burden of disease from exposure to second-hand smoke: A retrospective analysis of data from 192 countries. Lancet [Internet]. 2011;377(9760):139–46. Available from: http://dx.doi.org/10.1016/S0140-6736(10)61388-8
49. Pan X, Luo Y, Roberts AR. Secondhand Smoke and Women’s Cognitive Function in China. Am J Epidemiol. 2018;187(5):911–8.
50. Prince M, Albanese E, Guerchet M, Prina M. World Alzheimer Report 2014 Dementia and Risk Reduction An AnAlysis of pRotective AnD moDifiAble fActoRs EXECUTIVE SUMMARY dr Maëlenn Guerchet dr Matthew prina. 2014; Available from: www.daviddesigns.co.uk
51. Zotcheva E, Bergh S, Selbæk G, Krokstad S, Håberg AK, Strand BH, et al. Midlife physical activity, psychological distress, and dementia risk: The HUNT study. J Alzheimer’s Dis. 2018;66(2):825–33.
52. Bartels C, Wagner M, Wolfsgruber S, Ehrenreich H, Schneider A. Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer’s dementia in individuals with previous depression. Am J Psychiatry. 2018;175(3):232–41.
53. Power MC, Adar SD, Yanosky JD, Weuve J. Exposure to air pollution as a potential contributor to cognitive function, cognitive decline, brain imaging, and dementia: A systematic review of epidemiologic research. Neurotoxicology [Internet]. 2016;56:235–53. Available from: http://dx.doi.org/10.1016/j.neuro.2016.06.004
54. Chen H, Kwong JC, Copes R, Tu K, Villeneuve PJ, van Donkelaar A, et al. Living near major roads and the incidence of dementia, Parkinson’s disease, and multiple sclerosis: a population-based cohort study. Lancet. 2017;389(10070):718–26.
55. Oudin A, Segersson D, Adolfsson R, Forsberg B. Association between air pollution from residential wood burning and dementia incidence in a longitudinal study in Northern Sweden. PLoS One. 2018;13(6):1–15.
56. Oudin A, Forsberg B, Adolfsson AN, Lind N, Modig L, Nordin M, et al. Traffic-related air pollution and dementia incidence in Northern Sweden: A longitudinal study. Environ Health Perspect. 2016;124(3):306–12.
57. Carey IM, Anderson HR, Atkinson RW, Beevers SD, Cook DG, Strachan DP, et al. Are noise and air pollution related to the incidence of dementia? A cohort study in London, England. BMJ Open. 2018;8(9):1–11.
58. Peters R, Ee N, Peters J, Booth A, Mudway I, Anstey KJ. Air Pollution and Dementia: A Systematic Review. J Alzheimer’s Dis. 2019;70(s1):S145–63.
59. Bowe B, Xie Y, Yan YY, Al-Aly Z. Burden of Cause-Specific Mortality Associated with PM2.5 Air Pollution in the United States. JAMA Netw Open. 2019;2(11):1–16.
60. MacEdo AC, Balouch S, Tabet N. Is Sleep Disruption a Risk Factor for Alzheimer’s Disease? J Alzheimer’s Dis. 2017;58(4):993–1002.
61. Spira AP, Gamaldo AA, An Y, Wu MN, Simonsick EM, Bilgel M, et al. Self-reported sleep and β-amyloid deposition in community-dwelling older adults. JAMA Neurol. 2013;70(12):1537–43.
62. Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp Mol Med. 2015;47(November 2014):e148.
63. Yaffe K, Falvey CM, Hoang T. Connections between sleep and cognition in older adults. Lancet Neurol. 2014;13(10):1017–28.
64. Sindi S, Kåreholt I, Johansson L, Skoog J, Sjöberg L, Wang HX, et al. Sleep disturbances and dementia risk: A multicenter study. Alzheimer’s Dement. 2018;14(10):1235–42.
65. Irwin MR, Vitiello M V. Implications of sleep disturbance and inflammation for Alzheimer’s disease dementia. Lancet Neurol [Internet]. 2019;18(3):296–306. Available from: http://dx.doi.org/10.1016/S1474-4422(18)30450-2
66. Shi L, Chen SJ, Ma MY, Bao YP, Han Y, Wang YM, et al. Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. Sleep Med Rev [Internet]. 2018;40:4–16. Available from: http://dx.doi.org/10.1016/j.smrv.2017.06.010
67. Wen Y, Schwartz S, Borenstein AR, Wu Y, Morgan D, Anderson WM. Sleep , Cognitive impairment , and Alzheimer ’ s disease : A Systematic Review and Meta-Analysis. Sleep. 2017;40(1):1–18.
68. Tsutsui T, Muramatsu N. Japan’s universal long-term care system reform of 2005: Containing costs and realizing a vision. J Am Geriatr Soc. 2007;55(9):1458–63.
69. Sharma S, Mueller C, Stewart R, Veronese N, Vancampfort D, Koyanagi A, et al. Predictors of Falls and Fractures Leading to Hospitalization in People With Dementia: A Representative Cohort Study. J Am Med Dir Assoc [Internet]. 2018;19(7):607–12. Available from: https://doi.org/10.1016/j.jamda.2018.03.009
70. Banerjee S, Farina N, Daley S, Grosvenor W, Hughes L, Hebditch M, et al. How do we enhance undergraduate healthcare education in dementia? A review of the role of innovative approaches and development of the Time for Dementia Programme. Int J Geriatr Psychiatry. 2017;32(1):68–75.
71. Poblador-Plou B, Calderón-Larrañaga A, Marta-Moreno J, Hancco-Saavedra J, Sicras-Mainar A, Soljak M, et al. Comorbidity of dementia: A cross-sectional study of primary care older patients. BMC Psychiatry. 2014;14(1).
72. Rait G, Walters K, Bottomley C, Petersen I, Iliffe S, Nazareth I. Survival of people with clinical diagnosis of dementia in primary care: Cohort study. BMJ. 2010;341(7768):337.
73. Bauer K, Schwarzkopf L, Graessel E, Holle R. A claims data-based comparison of comorbidity in individuals with and without dementia. BMC Geriatr. 2014;14(1):1–13.
74. Bunn F, Burn AM, Goodman C, Rait G, Norton S, Robinson L, et al. Comorbidity and dementia: A scoping review of the literature. BMC Med. 2014;12(1).
75. Bennett HQ, Norton S, Bunn F, Robinson L, Rait G, Goodman C, et al. The impact of dementia on service use by individuals with a comorbid health condition: A comparison of two cross-sectional analyses conducted approximately 10 years apart. BMC Med. 2018;16(1):1–7.
76. Duong S, Patel T, Chang F. Dementia: What pharmacists need to know. Can Pharm J. 2017;150(2):118–29.
77. Race E, Verfaellie M. Remote memory function and dysfunction in Korsakoff’s syndrome. Neuropsychol Rev. 2012;22(2):105–16.
78. Koguchi K, Nakatsuji Y, Abe K, Sakoda S. Wernicke’s encephalopathy after glucose infusion. Neurology. 2004;62(3):512.
79. Licher S, De Bruijn RFAG, Wolters FJ, Zillikens MC, Ikram MA, Ikram MK. Vitamin D and the Risk of Dementia: The Rotterdam Study. J Alzheimer’s Dis. 2017;60(3):989–97.
80. Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PHM, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014;83(10):920–8.
81. Afzal S, Bojesen SE, Nordestgaard BG. Reduced 25-hydroxyvitamin D and risk of Alzheimer’s disease and vascular dementia. Alzheimer’s Dement [Internet]. 2014;10(3):296–302. Available from: http://dx.doi.org/10.1016/j.jalz.2013.05.1765
82. Genuis SJ, Kelln KL. Toxicant exposure and bioaccumulation: A common and potentially reversible cause of cognitive dysfunction and dementia. Behav Neurol. 2015;2015.
83. Lin JN, Lin CL, Lin MC, Lai CH, Lin HH, Yang CH, et al. Increased risk of dementia in patients with acute organophosphate and Carbamate poisoning: A Nationwide Population-Based Cohort Study. Med (United States). 2015;94(29):1–8.
84. Yegambaram M, Manivannan B, Beach T, Halden R. Role of Environmental Contaminants in the Etiology of Alzheimer’s Disease: A Review. Curr Alzheimer Res. 2015;12(2):116–46.
85. Karri V, Schuhmacher M, Kumar V. Heavy metals (Pb, Cd, As and MeHg) as risk factors for cognitive dysfunction: A general review of metal mixture mechanism in brain. Environ Toxicol Pharmacol [Internet]. 2016;48:203–13. Available from: http://dx.doi.org/10.1016/j.etap.2016.09.016
86. Tong Y, Yang H, Tian X, Wang H, Zhou T, Zhang S, et al. High manganese, a risk for Alzheimer’s disease: High manganese induces amyloid-β related cognitive impairment. J Alzheimer’s Dis. 2014;42(3):865–78.
87. Palareti G, Legnani C, Cosmi B, Antonucci E, Erba N, Poli D, et al. Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study. Int J Lab Hematol. 2016;38(1):42–9.
88. Annerbo S, Lökk J. A Clinical Review of the Association of Thyroid Stimulating Hormone and Cognitive Impairment. ISRN Endocrinol. 2013;2013:1–6.
89. Lee KA, Park KT, Yu HM, Jin HY, Baek HS, Park TS. Subacute thyroiditis presenting as acute psychosis: A case report and literature review. Korean J Intern Med. 2013;28(2):242–6.
90. Isaac ML, Larson EB. Medical conditions with neuropsychiatric manifestations. Med Clin North Am [Internet]. 2014;98(5):1193–208. Available from: http://dx.doi.org/10.1016/j.mcna.2014.06.012
91. Murray AM. Cognitive Impairment in the Aging Dialysis and Chronic Kidney Disease Populations: An Occult Burden. Adv Chronic Kidney Dis. 2008;15(2):123–32.
92. Lourida I, Thompson-Coon J, Dickens CM, Soni M, Kuźma E, Kos K, et al. Parathyroid hormone, cognitive function and dementia: A systematic review. PLoS One. 2015;10(5):1–16.
93. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672–713.
94. Knopman DS, Penman AD, Catellier DJ, Coker LH, Shibata DK, Sharrett AR, et al. Vascular risk factors and longitudinal changes on brain MRI: The ARIC study. Neurology. 2011;76(22):1879–85.
95. Shah NS, Vidal JS, Masaki K, Petrovitch H, Ross GW, Tilley C, et al. Midlife blood pressure, plasma β-amyloid, and the risk for alzheimer disease: The honolulu asia aging study. Hypertension. 2012;59(4):780–6.
96. Xiao X, Wu ZC, Chou KC. A multi-label classifier for predicting the subcellular localization of gram-negative bacterial proteins with both single and multiple sites. PLoS One. 2011;6(6).
97. American Psychiatric Association. Criteria Updates. DSM-5 Updat. 2018;14.
98. Poggesi A, Inzitari D, Pantoni L. Atrial Fibrillation and Cognition: Epidemiological Data and Possible Mechanisms. Stroke. 2015;46(11):3316–21.
99. De Bruijn RFAG, Heeringa J, Wolters FJ, Franco OH, Stricker BHC, Hofman A, et al. Association between atrial fibrillation and dementia in the general population. JAMA Neurol. 2015;72(11):1288–94.
100. Shastri A, Bangar S, Holmes J. Obstructive sleep apnoea and dementia: Is there a link? Int J Geriatr Psychiatry. 2016;31(4):404–9.
101. Van Dyk K, Towns S, Tatarina O, Yeung P, Dorrejo J, Zahodne LB, et al. Assessing Fluctuating Cognition in Dementia Diagnosis. Am J Alzheimers Dis Other Demen. 2016;31(2):137–43.
102. Pfistermeister B, Tümena T, Gaßmann KG, Maas R, Fromm MF. Anticholinergic burden and cognitive function in a large German cohort of hospitalized geriatric patients. PLoS One. 2017;12(2):1–13.
103. Larner AJ. Manual of Screeners for Dementia: : pragmatic test accuracy studies [Internet]. Manual of Screeners for Dementia. 2020. p. 172. Available from: https://books.google.es/books?hl=es&lr=&id=g53aDwAAQBAJ&oi=fnd&pg=PP1&dq=Manual+of+Screeners+for+Dementia:+:+pragmatic+test+accuracy+studies&ots=Sy6kQcllhL&sig=hn4E8zwVIMZmBcciASX2fFfLTFw&redir_esc=y#v=onepage&q=Manual of Screeners for Dementia%3A %3A pra
104. Larner AJ. Manual of Screeners for Dementia: : pragmatic test accuracy studies. Manual of Screeners for Dementia. 2020. p. 172.
105. Li G, Larson EB, Shofer JB, Crane PK, Gibbons LE, McCormick W, et al. Cognitive Trajectory Changes Over 20 Years Before Dementia Diagnosis: A Large Cohort Study. J Am Geriatr Soc. 2017;65(12):2627–33.
106. Cornelis E, Gorus E, Beyer I, Bautmans I, De Vriendt P. Early diagnosis of mild cognitive impairment and mild dementia through basic and instrumental activities of daily living: Development of a new evaluation tool. PLoS Med. 2017;14(3):1–22.
107. Abdin E, Vaingankar JA, Picco L, Chua BY, Prince M, Chong SA, et al. Validation of the short version of the 10/66 dementia diagnosis in multiethnic Asian older adults in Singapore. BMC Geriatr. 2017;17(1):1–9.
108. Salem LC, Vogel A, Ebstrup J, Linneberg A, Waldemar G. Subjective cognitive complaints included in diagnostic evaluation of dementia helps accurate diagnosis in a mixed memory clinic cohort. Int J Geriatr Psychiatry. 2015;30(12):1177–85.
109. Hildreth KL, Church S. Evaluation and Management of the Elderly Patient Presenting with Cognitive Complaints. Med Clin North Am. 2015;99(2):311–35.
110. Schott JM, Warren JD, Barkhof F, Rossor MN, Fox NC. Suspected early dementia. BMJ. 2011;343(7824):1–5.
111. Teipel SJ, Keller F, Thyrian JR, Strohmaier U, Altiner A, Hoffmann W, et al. Hippocampus and Basal Forebrain Volumetry for Dementia and Mild Cognitive Impairment Diagnosis: Could It Be Useful in Primary Care? J Alzheimer’s Dis. 2017;55(4):1379–94.
112. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey–Bloom J, Relkin N, et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Neurology. 2001;56(9):1143–53.
113. Harper L, Fumagalli GG, Barkhof F, Scheltens P, O’Brien JT, Bouwman F, et al. MRI visual rating scales in the diagnosis of dementia: Evaluation in 184 post-mortem confirmed cases. Brain. 2016;139(4):1211–25.
114. Shams S, Martola J, Granberg T, Li X, Shams M, Fereshtehnejad SM, et al. Cerebral microbleeds: Different prevalence, topography, and risk factors depending on dementia diagnosis-the Karolinska imaging dementia study. Am J Neuroradiol. 2015;36(4):661–6.
115. Filippi M, Agosta F, Barkhof F, Dubois B, Fox NC, Frisoni GB, et al. EFNS task force: The use of neuroimaging in the diagnosis of dementia. Eur J Neurol. 2012;19(12):1487–501.
116. Verhagen M V., Guit GL, Hafkamp GJ, Kalisvaart K. The impact of MRI combined with visual rating scales on the clinical diagnosis of dementia: a prospective study. Eur Radiol. 2016;26(6):1716–22.
117. O’Brien JT, Paling S, Barber R, Williams ED, Ballard C, McKeith IG, et al. Progressive brain atrophy on serial MRI in dementia with Lewy Bodies, AD, and vascular dementia. Neurology. 2001;56(10):1386–8.
118. Fox NC, Schott JM. Fox and Schott Lancet 2004. 2004;392–4.
119. Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with lewy bodies, Parkinson’s disease, and Alzheimer’s disease. J Alzheimer’s Dis. 2014;38(1):63–73.
120. Struyfs H, Van Broeck B, Timmers M, Fransen E, Sleegers K, Van Broeckhoven C, et al. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis. J Alzheimer’s Dis. 2015;45(3):813–22.
121. Grangeon L, Paquet C, Bombois S, Quillard-Muraine M, Martinaud O, Bourre B, et al. Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein. J Alzheimer’s Dis. 2016;51(3):905–13.
122. Krudop WA, Dols A, Kerssens CJ, Prins ND, Möller C, Schouws S, et al. Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. Dement Geriatr Cogn Disord. 2016;41(1–2):16–26.
123. Goossens J, Bjerke M, Struyfs H, Niemantsverdriet E, Somers C, Van Den Bossche T, et al. No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis. Alzheimer’s Res Ther. 2017;9(1):1–7.
124. Goldman JS. Genetic Testing and Counseling in the Diagnosis and Management of Young-Onset Dementias. Psychiatr Clin North Am [Internet]. 2015;38(2):295–308. Available from: http://dx.doi.org/10.1016/j.psc.2015.01.008
125. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. J Am Med Assoc. 1997;278(16):1349–56.
126. Villaseñor-Cabrera T, Guàrdia-Olmos J, Jiménez-Maldonado M, Rizo-Curiel G, Peró-Cebollero M. Sensitivity and specificity of the Mini-Mental State Examination in the Mexican population. Qual Quant. 2010;44(6):1105–12.
127. Morphology TC. No 主観的健康感を中心とした在宅高齢者における 健康関連指標に関する共分散構造分析Title.
128. Jitapunkul S, Pillay I, Ebrahim S. The abbreviated mental test: Its use and validity. Age Ageing. 1991;20(5):332–6.
129. Coen RF, McCarroll K, Casey M, McNulty H, Laird E, Molloy AM, et al. The Frontal Assessment Battery: Normative Performance in a Large Sample of Older Community-Dwelling Hospital Outpatient or General Practitioner Attenders. J Geriatr Psychiatry Neurol. 2016;29(6):338–43.
130. Brodaty H, Pond D, Kemp NM, Luscombe G, Harding L, Berman K, et al. The GPCOG: A new screening test for dementia designed for general practice. J Am Geriatr Soc. 2002;50(3):530–4.
131. Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM, et al. Screening for dementia with the Memory Impairment Screen. Neurology. 1999;52(2):231–8.
132. Kudlicka A, Martyr A, Bahar-Fuchs A, Woods B, Clare L. Cognitive rehabilitation for people with mild to moderate dementia. Cochrane Database Syst Rev. 2019;2019(8).
133. Lamb SE, Sheehan B, Atherton N, Nichols V, Collins H, Mistry D, et al. Dementia And Physical Activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: Randomised controlled trial. BMJ. 2018;361.
134. Teri L, Logsdon RG, McCurry SM, Pike KC, McGough EL. Translating an evidence-based multicomponent intervention for older adults with dementia and caregivers. Gerontologist. 2020;60(3):548–57.
135. White N, Leurent B, Lord K, Scott S, Jones L, Sampson EL. The management of behavioural and psychological symptoms of dementia in the acute general medical hospital: a longitudinal cohort study. Int J Geriatr Psychiatry. 2017;32(3):297–305.
136. Malone DC, McLaughlin TP, Wahl PM, Leibman C, Arrighi HM, Cziraky MJ, et al. Burden of Alzheimer’s disease and association with negative health outcomes. Vol. 15, American Journal of Managed Care. 2009. p. 481–8.
137. Sager MA, Rudberg MA, Jalaluddin M, Franke T, Inouye SK, Seth Landefeld C, et al. Hospital Admission Risk Profile (HARP): Identifying older patients at risk for functional decline following acute medical illness and hospitalization. J Am Geriatr Soc. 1996;44(3):251–7.
138. Zhao Y, Kuo TC, Weir S, Kramer MS, Ash AS. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer’s. BMC Health Serv Res. 2008;8:1–8.
139. Zhu CW, Cosentino S, Ornstein K, Gu Y, Andrews H, Stern Y. Use and cost of hospitalization in dementia: Longitudinal results from a community-based study. Int J Geriatr Psychiatry. 2015;30(8):833–41.
140. Zhu CW, Cosentino S, Ornstein KA, Gu Y, Andrews H, Stern Y. Interactive Effects of Dementia Severity and Comorbidities on Medicare Expenditures. J Alzheimer’s Dis. 2017;57(1):305–15.
141. Vroomen JMN, Bosmans JE, Eekhout I, Joling KJ, Van Mierlo LD, Meiland FJM, et al. The cost-effectiveness of two forms of case management compared to a control group for persons with dementia and their informal caregivers from a societal perspective. PLoS One. 2016;11(9):1–20.
142. Intrator O, Zinn J, Mor V. Nursing home characteristics and potentially preventable hospitalizations of long-stay residents. J Am Geriatr Soc. 2004;52(10):1730–6.
143. Grothaus L, Balch S, Larson EB. With Hospitalizations. Library (Lond). 2012;
144. Cooper C, Selwood A, Livingston G. Knowledge, detection, and reporting of abuse by health and social care professionals: A systematic review. Am J Geriatr Psychiatry [Internet]. 2009;17(10):826–38. Available from: http://dx.doi.org/10.1097/JGP.0b013e3181b0fa2e
145. Cooper C, Huzzey L, Livingston G. The effect of an educational intervention on junior doctors’ knowledge and practice in detecting and managing elder abuse. Int Psychogeriatrics. 2012;24(9):1447–53.
146. Richardson B, Kitchen G, Livingston G. The effect of education on knowledge and management of elder abuse: A randomized controlled trial. Age Ageing. 2002;31(5):335–41.
147. Bunn F, Goodman C, Sworn K, Rait G, Brayne C, Robinson L, et al. Psychosocial Factors That Shape Patient and Carer Experiences of Dementia Diagnosis and Treatment: A Systematic Review of Qualitative Studies. PLoS Med. 2012;9(10).
148. Livingston G, Leavey G, Manela M, Livingston D, Rait G, Sampson E, et al. Making decisions for people with dementia who lack capacity: Qualitative study of family carers in UK. BMJ. 2010;341(7771):494.
149. Karlawish JHT. Living with dementia: caregiver perspectives. Vol. 7, LDI issue brief. 2002. p. 1–4.
150. Tiedt S, Duering M, Barro C, Boeck AGJ, Bode FJ, Klein M, et al. Serum neurofilament light a biomarker of neuroaxonal injury after ischemic stroke. Neurology. 2018;91(14):E1338–47.
151. Hildreth KL, Church S. Evaluation and Management of the Elderly Patient Presenting with Cognitive Complaints. Med Clin North Am [Internet]. 2015;99(2):311–35. Available from: http://dx.doi.org/10.1016/j.mcna.2014.11.006
152. French J. Department of Health. IT in Business: A Business Manager’s Casebook. 2013. p. 44–52.
153. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Cmaj. 2007;176(5):627–32.
154. Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: Managing safety concerns. Am J Psychiatry. 2012;169(9):900–6.
155. Albert Schweitzer Hospital, Lambarene, Gabon, and Institute of Tropical Medicine, University of Tübingen, Tübingen G. 需要引用的霍奇金第二肿瘤new England Journal. N Engl J Med. 2011;365:687–96.
156. Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer’s Disease:A systematic review and meta-analysis. PLoS One. 2015;10(4):1–16.
157. National Institute for Health and Care Excellence (NICE). Dementia: Supporting people with dementia and their carers in health and social care (update) [Internet]. Clinical guideline 42. 2016. Available from: https://www.nice.org.uk/guidance/cg42/resources/guidance-dementia-pdf
158. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: Management of dementia (an evidence-based review) [RETIRED]. Neurology. 2001;56(9):1154–66.
159. O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. Vascular cognitive impairment. Lancet Neurol. 2003;2(2):89–98.
160. McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;2019(3):1–446.
161. D’Andrea G, Terrazzino S, Leon A, Fortin D, Perini F, Granella F, et al. Elevated levels of circulating trace amines in primary headaches. Neurology. 2004;62(10):1701–5.
162. Nicolll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: A case report. Nat Med. 2003;9(4):448–52.
163. Rebok GW, Ball K, Guey LT, Jones RN, Kim HY, King JW, et al. Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc. 2014;62(1):16–24.
164. Cheng ST, Chow PK, Song YQ, Yu ECS, Chan ACM, Lee TMC, et al. Mental and physical activities delay cognitive decline in older persons with dementia. Am J Geriatr Psychiatry [Internet]. 2014;22(1):63–74. Available from: http://dx.doi.org/10.1016/j.jagp.2013.01.060
165. Sánchez A, Maseda A, Marante-Moar MP, De Labra C, Lorenzo-López L, Millán-Calenti JC. Comparing the Effects of Multisensory Stimulation and Individualized Music Sessions on Elderly People with Severe Dementia: A Randomized Controlled Trial. J Alzheimer’s Dis. 2016;52(1):303–15.
166. Wang JJ. Group reminiscence therapy for cognitive and affective function of demented elderly in Taiwan. Int J Geriatr Psychiatry. 2007;22(12):1235–40.
167. Sink KM, Espeland MA, Castro CM, Church T, Cohen R, Dodson JA, et al. Effect of a 24-month physical activity intervention vs health education on cognitive outcomes in sedentary older adults: The LIFE randomized trial. JAMA - J Am Med Assoc. 2015;314(8):781–90.
168. Todd A, Akhter N, Cairns JM, Kasim A, Walton N, Ellison A, et al. The Pain Divide: A cross-sectional analysis of chronic pain prevalence, pain intensity and opioid utilisation in England. BMJ Open. 2018;8(7):1–9.
169. Möhler R, Richter T, Köpke S, Meyer G. Interventions for preventing and reducing the use of physical restraints in long-term geriatric care. Cochrane Database Syst Rev. 2011;(2).
170. McCabe MP, Bird M, Davison TE, Mellor D, MacPherson S, Hallford D, et al. An RCT to evaluate the utility of a clinical protocol for staff in the management of behavioral and psychological symptoms of dementia in residential aged-care settings. Aging Ment Heal. 2015;19(9):799–807.
171. Unwin BK, Loskutova N, Knicely P, Wood CD. Tools for Better Dementia Care Quality measures and clinical tools can bring focus and clarity to caring for patients with cognitive impairment and supporting their caregivers. 2019;(February):11–6. Available from: https://www.nhqualitycampaign.org/files/AntipsychoticAlternatives.pdf
172. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669–77.
173. Klein F. Risikofaktor Komorbiditäten bei COVID-19- Erkrankung. Pneumologie. 2020;74(10):640.
174. Wang H, Li T, Barbarino P, Gauthier S, Brodaty H, Molinuevo JL, et al. Dementia care during COVID-19. Lancet. 2020;395(10231):1190–1.
175. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
176. Liu KY, Howard R, Banerjee S, Comas-Herrera A, Goddard J, Knapp M, et al. Dementia wellbeing and COVID-19: Review and expert consensus on current research and knowledge gaps. Int J Geriatr Psychiatry. 2021;36(11):1597–639.
2. Gale SA, Acar D, Daffner KR. Dementia. Am J Med. 2018;131(10):1161–9.
3. Huber SJ, Shuttleworth EC, Bellchambers MJG, Clapp LE. Subcortical Dementia Neuropsychological Differences. 2015;10–2.
4. Albert ML, Feldman RG, Willis AL. The “subcortical dementia” of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1974;37(2):121–30.
5. El C, Mcguinness B, Herron B, Ap P. Dementia. 2015;84(April):79–87.
6. Calderon-Garcidueñas AL, Duyckaerts C. Alzheimer disease. Handb Clin Neurol. 2018;145:325–37.
7. Boller F, Mizutani T, Roessmann U, Gambetti P. Parkinson disease, dementia, and alzheimer disease: Clinicopathological correlations. Ann Neurol. 1980;7(4):329–35.
8. Sabbagh MN, Cooper K, DeLange J, Stoehr JD, Thind K, Lahti T, et al. Functional, Global and Cognitive Decline Correlates to Accumulation of Alzheimers Pathology in MCI and AD. Curr Alzheimer Res. 2010;7(4):280–6.
9. Beal E. Alzheimer disease: Nat Rev Neurol. 2011;7(9):474.
10. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10(2):122–6.
11. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–46.
12. Ahmadi-Abhari S, Guzman-Castillo M, Bandosz P, Shipley MJ, Muniz-Terrera G, Singh-Manoux A, et al. Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: Modelling study. BMJ. 2017;358(July):1–15.
13. Kingston A, Comas-Herrera A, Jagger C. Forecasting the care needs of the older population in England over the next 20 years: estimates from the Population Ageing and Care Simulation (PACSim) modelling study. Lancet Public Heal. 2018;3(9):e447–55.
14. Xu H, Garcia-Ptacek S, Jönsson L, Wimo A, Nordström P, Eriksdotter M. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology. 2021;96(17):e2220–30.
15. Valenzuela MJ, Sachdev P. Brain reserve and dementia: A systematic review. Psychol Med. 2006;36(4):441–54.
16. Valenzuela MJ. Brain reserve and the prevention of dementia. Curr Opin Psychiatry. 2008;21(3):296–302.
17. Wilson RS, De Mendes Leon CF, Barnes LL. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. Prim Care Companion J Clin Psychiatry. 2002;4(2):84–5.
18. Capone C, Faraco G, Park L, Cao X, Davisson RL, Iadecola C. The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am J Physiol - Hear Circ Physiol. 2011;300(1):397–407.
19. Luchsinger JA, Gustafson DR. Adiposity and Alzheimer’s disease. Curr Opin Clin Nutr Metab Care. 2009;12(1):15–21.
20. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–734.
21. Morkem R, Barber D, Williamson T, Patten SB. A Canadian primary care sentinel surveillance network study evaluating antidepressant prescribing in Canada from 2006 to 2012. Can J Psychiatry. 2015;60(12):564–70.
22. Emilsson JF, Andreasson U, Blennow K, Eriksson E, Zetterberg H. Comment on “An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice.” Sci Transl Med. 2014;6(268):268le5.
23. Yaffe K. Metabolic syndrome and cognitive disorders: Is the sum greater than its parts? Alzheimer Dis Assoc Disord. 2007;21(2):167–71.
24. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: An analysis of population-based data. Lancet Neurol. 2014;13(8):788–94.
25. Swan GE, Lessov-Schlaggar CN. The effects of tobacco smoke and nicotine on cognition and the brain. Neuropsychol Rev. 2007;17(3):259–73.
26. Yang YC, Boen C, Gerken K, Li T, Schorpp K, Harris KM. Social relationships and physiological determinants of longevity across the human life span. Proc Natl Acad Sci U S A. 2016;113(3):578–83.
27. Khaw KT, Wareham N, Bingham S, Welch A, Luben R, Day N. Combined impact of health behaviours and mortality in men and women: The EPIC-Norfolk prospective population study. PLoS Med. 2008;5(1):0039–47.
28. Sabia S, Dugravot A, Dartigues JF, Abell J, Elbaz A, Kivimäki M, et al. Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. BMJ [Internet]. 2017;357(June):1–12. Available from: http://dx.doi.org/doi:10.1136/bmj.j2709
29. Singh-Manoux A, Dugravot A, Fournier A, Abell J, Ebmeier K, Kivimäki M, et al. Trajectories of depressive symptoms before diagnosis of dementia: A 28-year follow-up study. JAMA Psychiatry. 2017;74(7):712–8.
30. Deckers K, Van Boxtel MPJ, Schiepers OJG, De Vugt M, Sánchez JLM, Anstey KJ, et al. Target risk factors for dementia prevention: A systematic review and Delphi consensus study on the evidence from observational studies. Int J Geriatr Psychiatry. 2015;30(3):234–46.
31. Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med. 2016;374(6):523–32.
32. Larsson SC, Traylor M, Malik R, Dichgans M, Burgess S, Markus HS. Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis. BMJ. 2017;359:j5375.
33. Kremen WS, Beck A, Elman JA, Gustavson DE, Reynolds CA, Tu XM, et al. Influence of young adult cognitive ability and additional education on later-life cognition. Proc Natl Acad Sci U S A. 2019;116(6):2021–6.
34. Blacker D, Weuve J. Brain exercise and brain outcomes: Does cognitive activity really work to maintain your brain? JAMA Psychiatry. 2018;75(7):703–4.
35. Lee ATC, Richards M, Chan WC, Chiu HFK, Lee RSY, Lam LCW. Association of daily intellectual activities with lower risk of incident dementia among older Chinese adults. JAMA Psychiatry. 2018;75(7):697–703.
36. Girouard H, Park L, Anrather J, Zhou P, Iadecola C. Cerebrovascular nitrosative stress mediates neurovascular and endothelial dysfunction induced by angiotensin II. Arterioscler Thromb Vasc Biol. 2007;27(2):303–9.
37. McGrath ER, Seshadri S. Author response: Blood pressure from mid- to late life and risk of incident dementia. Neurology. 2018;91(3):149.
38. Lane CA, Barnes J, Nicholas JM, Sudre CH, Cash DM, Parker TD, et al. Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. Lancet Neurol [Internet]. 2019;18(10):942–52. Available from: http://dx.doi.org/10.1016/S1474-4422(19)30228-5
39. Abell JG, Kivimäki M, Dugravot A, Tabak AG, Fayosse A, Shipley M, et al. Association between systolic blood pressure and dementia in theWhitehall II cohort study: Role of age, duration, and threshold used to define hypertension. Eur Heart J. 2018;39(33):3119–25.
40. Cholerton B, Larson EB, Baker LD, Craft S, Crane PK, Millard SP, et al. Neuropathologic correlates of cognition in a population-based sample. J Alzheimer’s Dis. 2013;36(4):699–709.
41. Chatterjee S, Peters SAE, Woodward M, Arango SM, Batty GD, Beckett N, et al. Type 2diabetes as a risk factor for dementia in women compared with men: A pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016;39(2):300–7.
42. Sabia S, Fayosse A, Dumurgier J, Schnitzler A, Empana JP, Ebmeier KP, et al. Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 Year follow-up of Whitehall II cohort study. BMJ. 2019;366:1–10.
43. Rehm J, Hasan OSM, Black SE, Shield KD, Schwarzinger M. Alcohol use and dementia: A systematic scoping review 11 Medical and Health Sciences 1117 Public Health and Health Services. Alzheimer’s Res Ther. 2019;11(1):1–11.
44. Schwarzinger M, Pollock BG, Hasan OSM, Dufouil C, Rehm J, Baillot S, et al. Contribution of alcohol use disorders to the burden of dementia in France 2008–13: a nationwide retrospective cohort study. Lancet Public Heal. 2018;3(3):e124–32.
45. Knutson JS. 基因的改变NIH Public Access. Bone [Internet]. 2014;23(1):1–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf
46. Debanne SM, Bielefeld RA, Cheruvu VK, Fritsch T, Rowland DY. Alzheimer’s disease and smoking: Bias in cohort studies. J Alzheimer’s Dis. 2007;11(3):313–21.
47. Choi D, Choi S, Park SM. Effect of smoking cessation on the risk of dementia: a longitudinal study. Ann Clin Transl Neurol. 2018;5(10):1192–9.
48. Öberg M, Jaakkola MS, Woodward A, Peruga A, Prüss-Ustün A. Worldwide burden of disease from exposure to second-hand smoke: A retrospective analysis of data from 192 countries. Lancet [Internet]. 2011;377(9760):139–46. Available from: http://dx.doi.org/10.1016/S0140-6736(10)61388-8
49. Pan X, Luo Y, Roberts AR. Secondhand Smoke and Women’s Cognitive Function in China. Am J Epidemiol. 2018;187(5):911–8.
50. Prince M, Albanese E, Guerchet M, Prina M. World Alzheimer Report 2014 Dementia and Risk Reduction An AnAlysis of pRotective AnD moDifiAble fActoRs EXECUTIVE SUMMARY dr Maëlenn Guerchet dr Matthew prina. 2014; Available from: www.daviddesigns.co.uk
51. Zotcheva E, Bergh S, Selbæk G, Krokstad S, Håberg AK, Strand BH, et al. Midlife physical activity, psychological distress, and dementia risk: The HUNT study. J Alzheimer’s Dis. 2018;66(2):825–33.
52. Bartels C, Wagner M, Wolfsgruber S, Ehrenreich H, Schneider A. Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer’s dementia in individuals with previous depression. Am J Psychiatry. 2018;175(3):232–41.
53. Power MC, Adar SD, Yanosky JD, Weuve J. Exposure to air pollution as a potential contributor to cognitive function, cognitive decline, brain imaging, and dementia: A systematic review of epidemiologic research. Neurotoxicology [Internet]. 2016;56:235–53. Available from: http://dx.doi.org/10.1016/j.neuro.2016.06.004
54. Chen H, Kwong JC, Copes R, Tu K, Villeneuve PJ, van Donkelaar A, et al. Living near major roads and the incidence of dementia, Parkinson’s disease, and multiple sclerosis: a population-based cohort study. Lancet. 2017;389(10070):718–26.
55. Oudin A, Segersson D, Adolfsson R, Forsberg B. Association between air pollution from residential wood burning and dementia incidence in a longitudinal study in Northern Sweden. PLoS One. 2018;13(6):1–15.
56. Oudin A, Forsberg B, Adolfsson AN, Lind N, Modig L, Nordin M, et al. Traffic-related air pollution and dementia incidence in Northern Sweden: A longitudinal study. Environ Health Perspect. 2016;124(3):306–12.
57. Carey IM, Anderson HR, Atkinson RW, Beevers SD, Cook DG, Strachan DP, et al. Are noise and air pollution related to the incidence of dementia? A cohort study in London, England. BMJ Open. 2018;8(9):1–11.
58. Peters R, Ee N, Peters J, Booth A, Mudway I, Anstey KJ. Air Pollution and Dementia: A Systematic Review. J Alzheimer’s Dis. 2019;70(s1):S145–63.
59. Bowe B, Xie Y, Yan YY, Al-Aly Z. Burden of Cause-Specific Mortality Associated with PM2.5 Air Pollution in the United States. JAMA Netw Open. 2019;2(11):1–16.
60. MacEdo AC, Balouch S, Tabet N. Is Sleep Disruption a Risk Factor for Alzheimer’s Disease? J Alzheimer’s Dis. 2017;58(4):993–1002.
61. Spira AP, Gamaldo AA, An Y, Wu MN, Simonsick EM, Bilgel M, et al. Self-reported sleep and β-amyloid deposition in community-dwelling older adults. JAMA Neurol. 2013;70(12):1537–43.
62. Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp Mol Med. 2015;47(November 2014):e148.
63. Yaffe K, Falvey CM, Hoang T. Connections between sleep and cognition in older adults. Lancet Neurol. 2014;13(10):1017–28.
64. Sindi S, Kåreholt I, Johansson L, Skoog J, Sjöberg L, Wang HX, et al. Sleep disturbances and dementia risk: A multicenter study. Alzheimer’s Dement. 2018;14(10):1235–42.
65. Irwin MR, Vitiello M V. Implications of sleep disturbance and inflammation for Alzheimer’s disease dementia. Lancet Neurol [Internet]. 2019;18(3):296–306. Available from: http://dx.doi.org/10.1016/S1474-4422(18)30450-2
66. Shi L, Chen SJ, Ma MY, Bao YP, Han Y, Wang YM, et al. Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. Sleep Med Rev [Internet]. 2018;40:4–16. Available from: http://dx.doi.org/10.1016/j.smrv.2017.06.010
67. Wen Y, Schwartz S, Borenstein AR, Wu Y, Morgan D, Anderson WM. Sleep , Cognitive impairment , and Alzheimer ’ s disease : A Systematic Review and Meta-Analysis. Sleep. 2017;40(1):1–18.
68. Tsutsui T, Muramatsu N. Japan’s universal long-term care system reform of 2005: Containing costs and realizing a vision. J Am Geriatr Soc. 2007;55(9):1458–63.
69. Sharma S, Mueller C, Stewart R, Veronese N, Vancampfort D, Koyanagi A, et al. Predictors of Falls and Fractures Leading to Hospitalization in People With Dementia: A Representative Cohort Study. J Am Med Dir Assoc [Internet]. 2018;19(7):607–12. Available from: https://doi.org/10.1016/j.jamda.2018.03.009
70. Banerjee S, Farina N, Daley S, Grosvenor W, Hughes L, Hebditch M, et al. How do we enhance undergraduate healthcare education in dementia? A review of the role of innovative approaches and development of the Time for Dementia Programme. Int J Geriatr Psychiatry. 2017;32(1):68–75.
71. Poblador-Plou B, Calderón-Larrañaga A, Marta-Moreno J, Hancco-Saavedra J, Sicras-Mainar A, Soljak M, et al. Comorbidity of dementia: A cross-sectional study of primary care older patients. BMC Psychiatry. 2014;14(1).
72. Rait G, Walters K, Bottomley C, Petersen I, Iliffe S, Nazareth I. Survival of people with clinical diagnosis of dementia in primary care: Cohort study. BMJ. 2010;341(7768):337.
73. Bauer K, Schwarzkopf L, Graessel E, Holle R. A claims data-based comparison of comorbidity in individuals with and without dementia. BMC Geriatr. 2014;14(1):1–13.
74. Bunn F, Burn AM, Goodman C, Rait G, Norton S, Robinson L, et al. Comorbidity and dementia: A scoping review of the literature. BMC Med. 2014;12(1).
75. Bennett HQ, Norton S, Bunn F, Robinson L, Rait G, Goodman C, et al. The impact of dementia on service use by individuals with a comorbid health condition: A comparison of two cross-sectional analyses conducted approximately 10 years apart. BMC Med. 2018;16(1):1–7.
76. Duong S, Patel T, Chang F. Dementia: What pharmacists need to know. Can Pharm J. 2017;150(2):118–29.
77. Race E, Verfaellie M. Remote memory function and dysfunction in Korsakoff’s syndrome. Neuropsychol Rev. 2012;22(2):105–16.
78. Koguchi K, Nakatsuji Y, Abe K, Sakoda S. Wernicke’s encephalopathy after glucose infusion. Neurology. 2004;62(3):512.
79. Licher S, De Bruijn RFAG, Wolters FJ, Zillikens MC, Ikram MA, Ikram MK. Vitamin D and the Risk of Dementia: The Rotterdam Study. J Alzheimer’s Dis. 2017;60(3):989–97.
80. Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PHM, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014;83(10):920–8.
81. Afzal S, Bojesen SE, Nordestgaard BG. Reduced 25-hydroxyvitamin D and risk of Alzheimer’s disease and vascular dementia. Alzheimer’s Dement [Internet]. 2014;10(3):296–302. Available from: http://dx.doi.org/10.1016/j.jalz.2013.05.1765
82. Genuis SJ, Kelln KL. Toxicant exposure and bioaccumulation: A common and potentially reversible cause of cognitive dysfunction and dementia. Behav Neurol. 2015;2015.
83. Lin JN, Lin CL, Lin MC, Lai CH, Lin HH, Yang CH, et al. Increased risk of dementia in patients with acute organophosphate and Carbamate poisoning: A Nationwide Population-Based Cohort Study. Med (United States). 2015;94(29):1–8.
84. Yegambaram M, Manivannan B, Beach T, Halden R. Role of Environmental Contaminants in the Etiology of Alzheimer’s Disease: A Review. Curr Alzheimer Res. 2015;12(2):116–46.
85. Karri V, Schuhmacher M, Kumar V. Heavy metals (Pb, Cd, As and MeHg) as risk factors for cognitive dysfunction: A general review of metal mixture mechanism in brain. Environ Toxicol Pharmacol [Internet]. 2016;48:203–13. Available from: http://dx.doi.org/10.1016/j.etap.2016.09.016
86. Tong Y, Yang H, Tian X, Wang H, Zhou T, Zhang S, et al. High manganese, a risk for Alzheimer’s disease: High manganese induces amyloid-β related cognitive impairment. J Alzheimer’s Dis. 2014;42(3):865–78.
87. Palareti G, Legnani C, Cosmi B, Antonucci E, Erba N, Poli D, et al. Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study. Int J Lab Hematol. 2016;38(1):42–9.
88. Annerbo S, Lökk J. A Clinical Review of the Association of Thyroid Stimulating Hormone and Cognitive Impairment. ISRN Endocrinol. 2013;2013:1–6.
89. Lee KA, Park KT, Yu HM, Jin HY, Baek HS, Park TS. Subacute thyroiditis presenting as acute psychosis: A case report and literature review. Korean J Intern Med. 2013;28(2):242–6.
90. Isaac ML, Larson EB. Medical conditions with neuropsychiatric manifestations. Med Clin North Am [Internet]. 2014;98(5):1193–208. Available from: http://dx.doi.org/10.1016/j.mcna.2014.06.012
91. Murray AM. Cognitive Impairment in the Aging Dialysis and Chronic Kidney Disease Populations: An Occult Burden. Adv Chronic Kidney Dis. 2008;15(2):123–32.
92. Lourida I, Thompson-Coon J, Dickens CM, Soni M, Kuźma E, Kos K, et al. Parathyroid hormone, cognitive function and dementia: A systematic review. PLoS One. 2015;10(5):1–16.
93. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672–713.
94. Knopman DS, Penman AD, Catellier DJ, Coker LH, Shibata DK, Sharrett AR, et al. Vascular risk factors and longitudinal changes on brain MRI: The ARIC study. Neurology. 2011;76(22):1879–85.
95. Shah NS, Vidal JS, Masaki K, Petrovitch H, Ross GW, Tilley C, et al. Midlife blood pressure, plasma β-amyloid, and the risk for alzheimer disease: The honolulu asia aging study. Hypertension. 2012;59(4):780–6.
96. Xiao X, Wu ZC, Chou KC. A multi-label classifier for predicting the subcellular localization of gram-negative bacterial proteins with both single and multiple sites. PLoS One. 2011;6(6).
97. American Psychiatric Association. Criteria Updates. DSM-5 Updat. 2018;14.
98. Poggesi A, Inzitari D, Pantoni L. Atrial Fibrillation and Cognition: Epidemiological Data and Possible Mechanisms. Stroke. 2015;46(11):3316–21.
99. De Bruijn RFAG, Heeringa J, Wolters FJ, Franco OH, Stricker BHC, Hofman A, et al. Association between atrial fibrillation and dementia in the general population. JAMA Neurol. 2015;72(11):1288–94.
100. Shastri A, Bangar S, Holmes J. Obstructive sleep apnoea and dementia: Is there a link? Int J Geriatr Psychiatry. 2016;31(4):404–9.
101. Van Dyk K, Towns S, Tatarina O, Yeung P, Dorrejo J, Zahodne LB, et al. Assessing Fluctuating Cognition in Dementia Diagnosis. Am J Alzheimers Dis Other Demen. 2016;31(2):137–43.
102. Pfistermeister B, Tümena T, Gaßmann KG, Maas R, Fromm MF. Anticholinergic burden and cognitive function in a large German cohort of hospitalized geriatric patients. PLoS One. 2017;12(2):1–13.
103. Larner AJ. Manual of Screeners for Dementia: : pragmatic test accuracy studies [Internet]. Manual of Screeners for Dementia. 2020. p. 172. Available from: https://books.google.es/books?hl=es&lr=&id=g53aDwAAQBAJ&oi=fnd&pg=PP1&dq=Manual+of+Screeners+for+Dementia:+:+pragmatic+test+accuracy+studies&ots=Sy6kQcllhL&sig=hn4E8zwVIMZmBcciASX2fFfLTFw&redir_esc=y#v=onepage&q=Manual of Screeners for Dementia%3A %3A pra
104. Larner AJ. Manual of Screeners for Dementia: : pragmatic test accuracy studies. Manual of Screeners for Dementia. 2020. p. 172.
105. Li G, Larson EB, Shofer JB, Crane PK, Gibbons LE, McCormick W, et al. Cognitive Trajectory Changes Over 20 Years Before Dementia Diagnosis: A Large Cohort Study. J Am Geriatr Soc. 2017;65(12):2627–33.
106. Cornelis E, Gorus E, Beyer I, Bautmans I, De Vriendt P. Early diagnosis of mild cognitive impairment and mild dementia through basic and instrumental activities of daily living: Development of a new evaluation tool. PLoS Med. 2017;14(3):1–22.
107. Abdin E, Vaingankar JA, Picco L, Chua BY, Prince M, Chong SA, et al. Validation of the short version of the 10/66 dementia diagnosis in multiethnic Asian older adults in Singapore. BMC Geriatr. 2017;17(1):1–9.
108. Salem LC, Vogel A, Ebstrup J, Linneberg A, Waldemar G. Subjective cognitive complaints included in diagnostic evaluation of dementia helps accurate diagnosis in a mixed memory clinic cohort. Int J Geriatr Psychiatry. 2015;30(12):1177–85.
109. Hildreth KL, Church S. Evaluation and Management of the Elderly Patient Presenting with Cognitive Complaints. Med Clin North Am. 2015;99(2):311–35.
110. Schott JM, Warren JD, Barkhof F, Rossor MN, Fox NC. Suspected early dementia. BMJ. 2011;343(7824):1–5.
111. Teipel SJ, Keller F, Thyrian JR, Strohmaier U, Altiner A, Hoffmann W, et al. Hippocampus and Basal Forebrain Volumetry for Dementia and Mild Cognitive Impairment Diagnosis: Could It Be Useful in Primary Care? J Alzheimer’s Dis. 2017;55(4):1379–94.
112. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey–Bloom J, Relkin N, et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Neurology. 2001;56(9):1143–53.
113. Harper L, Fumagalli GG, Barkhof F, Scheltens P, O’Brien JT, Bouwman F, et al. MRI visual rating scales in the diagnosis of dementia: Evaluation in 184 post-mortem confirmed cases. Brain. 2016;139(4):1211–25.
114. Shams S, Martola J, Granberg T, Li X, Shams M, Fereshtehnejad SM, et al. Cerebral microbleeds: Different prevalence, topography, and risk factors depending on dementia diagnosis-the Karolinska imaging dementia study. Am J Neuroradiol. 2015;36(4):661–6.
115. Filippi M, Agosta F, Barkhof F, Dubois B, Fox NC, Frisoni GB, et al. EFNS task force: The use of neuroimaging in the diagnosis of dementia. Eur J Neurol. 2012;19(12):1487–501.
116. Verhagen M V., Guit GL, Hafkamp GJ, Kalisvaart K. The impact of MRI combined with visual rating scales on the clinical diagnosis of dementia: a prospective study. Eur Radiol. 2016;26(6):1716–22.
117. O’Brien JT, Paling S, Barber R, Williams ED, Ballard C, McKeith IG, et al. Progressive brain atrophy on serial MRI in dementia with Lewy Bodies, AD, and vascular dementia. Neurology. 2001;56(10):1386–8.
118. Fox NC, Schott JM. Fox and Schott Lancet 2004. 2004;392–4.
119. Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with lewy bodies, Parkinson’s disease, and Alzheimer’s disease. J Alzheimer’s Dis. 2014;38(1):63–73.
120. Struyfs H, Van Broeck B, Timmers M, Fransen E, Sleegers K, Van Broeckhoven C, et al. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis. J Alzheimer’s Dis. 2015;45(3):813–22.
121. Grangeon L, Paquet C, Bombois S, Quillard-Muraine M, Martinaud O, Bourre B, et al. Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein. J Alzheimer’s Dis. 2016;51(3):905–13.
122. Krudop WA, Dols A, Kerssens CJ, Prins ND, Möller C, Schouws S, et al. Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. Dement Geriatr Cogn Disord. 2016;41(1–2):16–26.
123. Goossens J, Bjerke M, Struyfs H, Niemantsverdriet E, Somers C, Van Den Bossche T, et al. No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis. Alzheimer’s Res Ther. 2017;9(1):1–7.
124. Goldman JS. Genetic Testing and Counseling in the Diagnosis and Management of Young-Onset Dementias. Psychiatr Clin North Am [Internet]. 2015;38(2):295–308. Available from: http://dx.doi.org/10.1016/j.psc.2015.01.008
125. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. J Am Med Assoc. 1997;278(16):1349–56.
126. Villaseñor-Cabrera T, Guàrdia-Olmos J, Jiménez-Maldonado M, Rizo-Curiel G, Peró-Cebollero M. Sensitivity and specificity of the Mini-Mental State Examination in the Mexican population. Qual Quant. 2010;44(6):1105–12.
127. Morphology TC. No 主観的健康感を中心とした在宅高齢者における 健康関連指標に関する共分散構造分析Title.
128. Jitapunkul S, Pillay I, Ebrahim S. The abbreviated mental test: Its use and validity. Age Ageing. 1991;20(5):332–6.
129. Coen RF, McCarroll K, Casey M, McNulty H, Laird E, Molloy AM, et al. The Frontal Assessment Battery: Normative Performance in a Large Sample of Older Community-Dwelling Hospital Outpatient or General Practitioner Attenders. J Geriatr Psychiatry Neurol. 2016;29(6):338–43.
130. Brodaty H, Pond D, Kemp NM, Luscombe G, Harding L, Berman K, et al. The GPCOG: A new screening test for dementia designed for general practice. J Am Geriatr Soc. 2002;50(3):530–4.
131. Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM, et al. Screening for dementia with the Memory Impairment Screen. Neurology. 1999;52(2):231–8.
132. Kudlicka A, Martyr A, Bahar-Fuchs A, Woods B, Clare L. Cognitive rehabilitation for people with mild to moderate dementia. Cochrane Database Syst Rev. 2019;2019(8).
133. Lamb SE, Sheehan B, Atherton N, Nichols V, Collins H, Mistry D, et al. Dementia And Physical Activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: Randomised controlled trial. BMJ. 2018;361.
134. Teri L, Logsdon RG, McCurry SM, Pike KC, McGough EL. Translating an evidence-based multicomponent intervention for older adults with dementia and caregivers. Gerontologist. 2020;60(3):548–57.
135. White N, Leurent B, Lord K, Scott S, Jones L, Sampson EL. The management of behavioural and psychological symptoms of dementia in the acute general medical hospital: a longitudinal cohort study. Int J Geriatr Psychiatry. 2017;32(3):297–305.
136. Malone DC, McLaughlin TP, Wahl PM, Leibman C, Arrighi HM, Cziraky MJ, et al. Burden of Alzheimer’s disease and association with negative health outcomes. Vol. 15, American Journal of Managed Care. 2009. p. 481–8.
137. Sager MA, Rudberg MA, Jalaluddin M, Franke T, Inouye SK, Seth Landefeld C, et al. Hospital Admission Risk Profile (HARP): Identifying older patients at risk for functional decline following acute medical illness and hospitalization. J Am Geriatr Soc. 1996;44(3):251–7.
138. Zhao Y, Kuo TC, Weir S, Kramer MS, Ash AS. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer’s. BMC Health Serv Res. 2008;8:1–8.
139. Zhu CW, Cosentino S, Ornstein K, Gu Y, Andrews H, Stern Y. Use and cost of hospitalization in dementia: Longitudinal results from a community-based study. Int J Geriatr Psychiatry. 2015;30(8):833–41.
140. Zhu CW, Cosentino S, Ornstein KA, Gu Y, Andrews H, Stern Y. Interactive Effects of Dementia Severity and Comorbidities on Medicare Expenditures. J Alzheimer’s Dis. 2017;57(1):305–15.
141. Vroomen JMN, Bosmans JE, Eekhout I, Joling KJ, Van Mierlo LD, Meiland FJM, et al. The cost-effectiveness of two forms of case management compared to a control group for persons with dementia and their informal caregivers from a societal perspective. PLoS One. 2016;11(9):1–20.
142. Intrator O, Zinn J, Mor V. Nursing home characteristics and potentially preventable hospitalizations of long-stay residents. J Am Geriatr Soc. 2004;52(10):1730–6.
143. Grothaus L, Balch S, Larson EB. With Hospitalizations. Library (Lond). 2012;
144. Cooper C, Selwood A, Livingston G. Knowledge, detection, and reporting of abuse by health and social care professionals: A systematic review. Am J Geriatr Psychiatry [Internet]. 2009;17(10):826–38. Available from: http://dx.doi.org/10.1097/JGP.0b013e3181b0fa2e
145. Cooper C, Huzzey L, Livingston G. The effect of an educational intervention on junior doctors’ knowledge and practice in detecting and managing elder abuse. Int Psychogeriatrics. 2012;24(9):1447–53.
146. Richardson B, Kitchen G, Livingston G. The effect of education on knowledge and management of elder abuse: A randomized controlled trial. Age Ageing. 2002;31(5):335–41.
147. Bunn F, Goodman C, Sworn K, Rait G, Brayne C, Robinson L, et al. Psychosocial Factors That Shape Patient and Carer Experiences of Dementia Diagnosis and Treatment: A Systematic Review of Qualitative Studies. PLoS Med. 2012;9(10).
148. Livingston G, Leavey G, Manela M, Livingston D, Rait G, Sampson E, et al. Making decisions for people with dementia who lack capacity: Qualitative study of family carers in UK. BMJ. 2010;341(7771):494.
149. Karlawish JHT. Living with dementia: caregiver perspectives. Vol. 7, LDI issue brief. 2002. p. 1–4.
150. Tiedt S, Duering M, Barro C, Boeck AGJ, Bode FJ, Klein M, et al. Serum neurofilament light a biomarker of neuroaxonal injury after ischemic stroke. Neurology. 2018;91(14):E1338–47.
151. Hildreth KL, Church S. Evaluation and Management of the Elderly Patient Presenting with Cognitive Complaints. Med Clin North Am [Internet]. 2015;99(2):311–35. Available from: http://dx.doi.org/10.1016/j.mcna.2014.11.006
152. French J. Department of Health. IT in Business: A Business Manager’s Casebook. 2013. p. 44–52.
153. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Cmaj. 2007;176(5):627–32.
154. Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: Managing safety concerns. Am J Psychiatry. 2012;169(9):900–6.
155. Albert Schweitzer Hospital, Lambarene, Gabon, and Institute of Tropical Medicine, University of Tübingen, Tübingen G. 需要引用的霍奇金第二肿瘤new England Journal. N Engl J Med. 2011;365:687–96.
156. Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer’s Disease:A systematic review and meta-analysis. PLoS One. 2015;10(4):1–16.
157. National Institute for Health and Care Excellence (NICE). Dementia: Supporting people with dementia and their carers in health and social care (update) [Internet]. Clinical guideline 42. 2016. Available from: https://www.nice.org.uk/guidance/cg42/resources/guidance-dementia-pdf
158. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: Management of dementia (an evidence-based review) [RETIRED]. Neurology. 2001;56(9):1154–66.
159. O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. Vascular cognitive impairment. Lancet Neurol. 2003;2(2):89–98.
160. McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;2019(3):1–446.
161. D’Andrea G, Terrazzino S, Leon A, Fortin D, Perini F, Granella F, et al. Elevated levels of circulating trace amines in primary headaches. Neurology. 2004;62(10):1701–5.
162. Nicolll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: A case report. Nat Med. 2003;9(4):448–52.
163. Rebok GW, Ball K, Guey LT, Jones RN, Kim HY, King JW, et al. Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc. 2014;62(1):16–24.
164. Cheng ST, Chow PK, Song YQ, Yu ECS, Chan ACM, Lee TMC, et al. Mental and physical activities delay cognitive decline in older persons with dementia. Am J Geriatr Psychiatry [Internet]. 2014;22(1):63–74. Available from: http://dx.doi.org/10.1016/j.jagp.2013.01.060
165. Sánchez A, Maseda A, Marante-Moar MP, De Labra C, Lorenzo-López L, Millán-Calenti JC. Comparing the Effects of Multisensory Stimulation and Individualized Music Sessions on Elderly People with Severe Dementia: A Randomized Controlled Trial. J Alzheimer’s Dis. 2016;52(1):303–15.
166. Wang JJ. Group reminiscence therapy for cognitive and affective function of demented elderly in Taiwan. Int J Geriatr Psychiatry. 2007;22(12):1235–40.
167. Sink KM, Espeland MA, Castro CM, Church T, Cohen R, Dodson JA, et al. Effect of a 24-month physical activity intervention vs health education on cognitive outcomes in sedentary older adults: The LIFE randomized trial. JAMA - J Am Med Assoc. 2015;314(8):781–90.
168. Todd A, Akhter N, Cairns JM, Kasim A, Walton N, Ellison A, et al. The Pain Divide: A cross-sectional analysis of chronic pain prevalence, pain intensity and opioid utilisation in England. BMJ Open. 2018;8(7):1–9.
169. Möhler R, Richter T, Köpke S, Meyer G. Interventions for preventing and reducing the use of physical restraints in long-term geriatric care. Cochrane Database Syst Rev. 2011;(2).
170. McCabe MP, Bird M, Davison TE, Mellor D, MacPherson S, Hallford D, et al. An RCT to evaluate the utility of a clinical protocol for staff in the management of behavioral and psychological symptoms of dementia in residential aged-care settings. Aging Ment Heal. 2015;19(9):799–807.
171. Unwin BK, Loskutova N, Knicely P, Wood CD. Tools for Better Dementia Care Quality measures and clinical tools can bring focus and clarity to caring for patients with cognitive impairment and supporting their caregivers. 2019;(February):11–6. Available from: https://www.nhqualitycampaign.org/files/AntipsychoticAlternatives.pdf
172. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669–77.
173. Klein F. Risikofaktor Komorbiditäten bei COVID-19- Erkrankung. Pneumologie. 2020;74(10):640.
174. Wang H, Li T, Barbarino P, Gauthier S, Brodaty H, Molinuevo JL, et al. Dementia care during COVID-19. Lancet. 2020;395(10231):1190–1.
175. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
176. Liu KY, Howard R, Banerjee S, Comas-Herrera A, Goddard J, Knapp M, et al. Dementia wellbeing and COVID-19: Review and expert consensus on current research and knowledge gaps. Int J Geriatr Psychiatry. 2021;36(11):1597–639.
Crossmark
Statistics
321 Views | 28 Downloads
How to Cite
1.
Kaur J, Melkani I, Singh AP, Singh AP, Bala K. An Overview on Dementia: A Major Symptom of Alzheimer’s Disease. JDDT [Internet]. 15Jul.2022 [cited 19Apr.2024];12(4):189-04. Available from: https://jddtonline.info/index.php/jddt/article/view/5445
Section
Review
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.